Cambrex completes pilot plant expansion at its High Point, NC facility

16 May 2018

Site's reactor capacity is increased by 30%.

Cambrex has completed a pilot plant expansion at its High Point, NC facility with the installation and commissioning of a fourth reactor suite, increasing the site's reactor capacity by around 30%.

Cambrex completes pilot plant expansion at its High Point, NC facility

The new 400-sq ft suite includes two 2,000-L glass-lined reactors and a 0.6 m2 Hastelloy C22 filter dryer, allowing the manufacture of batch sizes typically 10-100 kg under cGMP conditions for clinical-phase projects.

The High Point site has also completed and implemented an upgrade of its analytical chromatography data systems for QC and analytical R&D to new, Empower 3 software. Empower brings enhanced capability, integrity and compliance to the site’s analytical systems, in line with the increasingly stringent demands of the FDA and EMA among other agencies.

In a further announcement, Cambrex has reported that structural steelwork and foundations are now in place for a new $24 million facility at its Charles City, Iowa plant, for the manufacture of highly potent APIs (HPAPIs).

The 4,500-sq ft production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m³ and will have a total reactor capacity of 2,200 gallons, consisting of a range of 200, 500 and 1,000 gallon glass and Hastelloy vessels to manufacture batches from 50 to 300 kg.

The project will also see the reconfiguration of the existing small-scale manufacturing area, providing a single high containment building to support early-stage development and manufacturing, providing flexibility across a broad range of scale. The facility is expected to be operational in the first half of 2019.

“Both of these US investments will enhance Cambrex’s cGMP capabilities and offer our customers expanded technologies and services,” commented Shawn Cavanagh, COO of Cambrex. He added: “We will continue to strategically invest across our global network of sites at all scales, from clinical through to commercial, to address customer demands and market requirements.”

Cambrex recently announced that it had also completed the construction and validation of a new 11,000 sq. ft. analytical laboratory at its High Point facility, as well as completing the installation of multiple continuous flow reactor platforms.

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more